Pharmaq AS v. Intervet International B.V. and Intervet Norge AS, Borgarting Court of Appeal, Norway, 22 December 2011, Case No. 10-103765ASD-BORG/03
On 22 December 2011 the Borgarting Court of Appeal rendered its decision in the case between Pharmaq AS (hereafter Pharmaq), and Intervet International B.V. and Intervet Norge AS (hereafter Intervet) regarding Intervet’s patent NO 317547.
NO 317547 concerns an isolated biological material in the form of a virus used in the development and production of vaccine against a disease affecting farmed fish, such as Atlantic salmon. The disease affects the fish pancreas and is called pancreatic disease. Biological materials are, in accordance to Norwegian law and its international obligations, considered patentable and qualify as an invention as long as certain requirements are fulfilled.
Read an extended summary in English, provided by Grette, here.
Read the judgment (in Norwegian) here.
Comments